TY - JOUR
T1 - Impact of tricyclic antidepressants, selective serotonin reuptake inhibitors, and other antidepressants on overall survival of patients with advanced lung cancer from 2004 to 2014
T2 - University of Cincinnati experience
AU - Abdel Karim, Nagla Fawzy
AU - Hassan, Rammey
AU - Siddiqi, Nabeela Iffat
AU - Eldessouki, Ihab
AU - Gaber, Ola
AU - Rahouma, Mohamed
AU - Kamel, Mohamed
AU - Yellu, Mhender
AU - Gulati, Shuchi
AU - Xie, Changchun
AU - Magdy, Mohamed
AU - Pruemer, Jane
N1 - Publisher Copyright:
© The Author(s) 2019.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Objectives: To evaluate and categorize the survival benefit of tricyclic antidepressants (TCAs) in lung cancer patients based on systematic computational drug repositioning data. Methods: Data were retrospectively extracted from the medical records of non-small cell lung cancer (NSCLC) patients from the University of Cincinnati Cancer Medical Center database. Patients receiving antidepressants during their course of anti-cancer treatment were compared with those without antidepressants. Data were analyzed using Kaplan–Meier survival curves with the log-rank test, and overall survival (OS) was calculated from the date of diagnosis until last follow-up or death. Results: The median OS at 2 and 5 years for patients on antidepressants was 20.3 months (54.7% and 42%) vs 44.3 months (47.6% and 43.2%), which was not significant. The median OS for patients receiving TCAs, selective serotonin reuptake inhibitors, and other antidepressants was 3.17 months, 31.33 months, and 18.50 months, respectively. Conclusion: We found no significant survival benefit for TCA use in combination with anti-cancer agents in NSCLC patients.
AB - Objectives: To evaluate and categorize the survival benefit of tricyclic antidepressants (TCAs) in lung cancer patients based on systematic computational drug repositioning data. Methods: Data were retrospectively extracted from the medical records of non-small cell lung cancer (NSCLC) patients from the University of Cincinnati Cancer Medical Center database. Patients receiving antidepressants during their course of anti-cancer treatment were compared with those without antidepressants. Data were analyzed using Kaplan–Meier survival curves with the log-rank test, and overall survival (OS) was calculated from the date of diagnosis until last follow-up or death. Results: The median OS at 2 and 5 years for patients on antidepressants was 20.3 months (54.7% and 42%) vs 44.3 months (47.6% and 43.2%), which was not significant. The median OS for patients receiving TCAs, selective serotonin reuptake inhibitors, and other antidepressants was 3.17 months, 31.33 months, and 18.50 months, respectively. Conclusion: We found no significant survival benefit for TCA use in combination with anti-cancer agents in NSCLC patients.
KW - Lung cancer
KW - SSRIs
KW - apoptosis
KW - drug repositioning
KW - overall survival
KW - tricyclic antidepressants
UR - http://www.scopus.com/inward/record.url?scp=85076450010&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076450010&partnerID=8YFLogxK
U2 - 10.1177/0300060519862469
DO - 10.1177/0300060519862469
M3 - Article
C2 - 31640444
AN - SCOPUS:85076450010
SN - 0300-0605
VL - 47
SP - 6016
EP - 6026
JO - Journal of International Medical Research
JF - Journal of International Medical Research
IS - 12
ER -